Core Insights - The company held an investor meeting on September 19, discussing its ongoing projects and financial performance [1][2] - The "Semaglutide Injection" project with Novartis is currently in the Phase III clinical trial follow-up stage, which is expected to positively impact future operating performance [1] - The company focuses on providing CRO services primarily for innovative drugs across various therapeutic areas [1] Group 1: Project Development - The company is developing several innovative drugs, including a traditional Chinese medicine for chronic heart failure and a small molecule new drug for high uric acid levels [2] - Currently, there are no self-developed projects in the oncology field, but the company provides clinical research services for multiple oncology drugs [2] - The timeline for research and development is influenced by project progress and the sponsor's investment [2] Group 2: Financial Management - The company emphasizes improving operational quality as the core of its market value management [2] - Idle cash is primarily invested in low-risk, high-liquidity financial products rather than high-risk securities or derivatives [2] - For the first half of 2025, the company's R&D investment was approximately 23.2 million, accounting for about 6% of revenue, which is higher than the net profit for the same period [2]

Group 1: Company Overview - Boji Pharmaceutical Technology Co., Ltd. primarily operates as a CRO service provider, offering outsourced pharmaceutical research and development services, focusing on innovative drugs across various therapeutic areas [2][4]. - The company has multiple self-developed projects at different research stages, although none have reached the market sales stage yet [4]. Group 2: Clinical Trials and Product Development - The project involving "Semaglutide Injection" is currently in the clinical trial follow-up phase, with the timeline for completion and market application dependent on project progress and client drug approval schedules [3][4]. - Current research projects include traditional Chinese medicine innovative drugs for chronic heart failure and small molecule new drugs for conditions like hyperuricemia and reversible cataracts [4]. Group 3: Financial Performance and Market Position - The company emphasizes improving operational quality as a core aspect of market value management, acknowledging the disparity between its stock price and the performance of innovative drug indices [5]. - For the first half of 2025, the company's R&D expenditure was approximately 2,320,000 yuan, accounting for about 6% of its revenue [6]. Group 4: Investment and Asset Management - The company manages idle funds by investing in safe, liquid, and low-risk financial products, avoiding high-risk investments such as stock trading or derivatives [6].

Group 1 - Huadian Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] - Cisco Ray's 2022 annual report was found to have inflated revenue by 9.96 million and profit by 7.0054 million, leading to penalties and a change in stock name to ST Cisco Ray [3] - Tianpu Co., Ltd. experienced a 245.20% increase in stock price over 13 consecutive trading days, indicating a risk of rapid decline [4] - ST New Power is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6] - Baoli International intends to invest in semiconductor testing equipment company Hongtai Technology, acquiring 1%-3% equity [7] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Shiqi Future, focusing on smart vision technology [8] Group 2 - SF Holding reported a revenue of 24.787 billion yuan in August, a year-on-year increase of 7.86% [9] - Various companies are involved in share transfers, including Guangli Micro and *ST Tianlong, with plans for significant asset restructuring [11] - Xinwangda's subsidiary aims to establish a storage industry fund with professional investment institutions [12] - Several companies are planning share repurchases, including Shunhao Co. and Lingyun Optics, with adjustments to repurchase plans [18]

Core Viewpoint - The company Boji Pharmaceutical Technology Co., Ltd. has received a new invention patent from the National Intellectual Property Administration, which enhances the detection method of gallic acid in berberine, contributing to the pharmaceutical ingredient testing field [1]. Group 1 - The patent is titled "A Method for Determining Gallic Acid in Berberine" [1] - The invention provides a method that achieves good separation of tannic acid, berberine, and gallic acid, with short detection time and high separation efficiency [1] - This method lays a solid foundation for controlling the safety and stability of berberine [1]

Group 1 - Company obtained an invention patent certificate from the National Intellectual Property Administration for a method to measure gallic acid in berberine [1] - As of the report date, the market capitalization of the company is 4 billion yuan [3] Group 2 - For the first half of 2025, the company's revenue composition shows that the service industry accounts for 99.46%, while other businesses account for 0.54% [2]

南财智讯9月19日电，博济医药发布公告称，公司近日收到国家知识产权局颁发的1项《发明专利证 书》。专利名称为"一种测定鞣酸小檗碱中没食子酸的方法"。 ...

近日，博济医药科技股份有限公司获国家知识产权局颁发的一项发明专利证书。专利名称为"一种测定 鞣酸小檗碱中没食子酸的方法"，证书号第8272934号，专利号ZL202510318197.1，申请日为2025年3月 18日，授权公告日为2025年9月19日。该方法涉及药品成分检测领域，能实现鞣酸、小檗碱和没食子酸 良好分离，检测时间短、分离度高。此专利虽对公司经营业绩无重大影响，但利于公司技术创新，完善 知识产权保护体系，提升核心竞争力。 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-076 二、对公司的影响 该专利的获得对公司经营业绩不会产生重大影响，但有利于公司的技术创新， 完善知识产权保护体系，充分发挥公司的自主知识产权优势，形成持续创新机制， 提升公司核心竞争力。 特此公告。 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的一项发明专利证书，具体情况如下： 一、专利基本情况 | 序号 | 发明名称 | 专利权人 | 证书号 | 专利号 | 专利申请日 | | 授权公告日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种测定鞣酸小 檗碱中没食子酸 | 博济医药科 技股份有限 | 第8272934号 | ZL 2025 1 | 2025 年 03 | | 2025 年 | 09 | | | | | | 0318197.1 | 月 18 | 日 | 月 19 ...

Core Viewpoint - Boji Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 22.96% but a recent decline over the past 20 days of 13.27% [1][2] Company Overview - Boji Pharmaceutical, established on September 29, 2002, and listed on April 24, 2015, is located in Guangzhou, Guangdong Province. The company specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of Boji Pharmaceutical includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from other sources [1] Financial Performance - For the first half of 2025, Boji Pharmaceutical achieved an operating income of 361 million yuan, representing a year-on-year growth of 5.88%. However, the net profit attributable to shareholders decreased by 48.33% to 15.57 million yuan [2] - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.76 million yuan in dividends, with 12.08 million yuan distributed over the past three years [3] Market Activity - As of September 17, Boji Pharmaceutical's stock price was 10.72 yuan per share, with a market capitalization of 4.133 billion yuan. The stock saw a net outflow of 7.18 million yuan in principal funds [1] - The company has a shareholder base of 24,900, which has decreased by 6.89% compared to the previous period, while the average number of circulating shares per person increased by 7.52% to 11,200 shares [2]

Core Viewpoint - The company has announced the use of idle funds for cash management, aiming to enhance fund utilization efficiency while ensuring operational needs and safety [1][3]. Group 1: Investment Details - The company plans to use up to RMB 250 million of idle self-owned funds for cash management, with the funds being able to roll over within a 12-month period [1]. - The investment objective is to achieve capital preservation and appreciation while safeguarding shareholder interests [1]. - The selected investment products will be high in safety, good in liquidity, and controllable in risk, ensuring no impact on the company's normal operational funds [1]. Group 2: Risk Analysis and Control - The company acknowledges that financial market fluctuations can impact investment outcomes, and thus, it will adhere to prudent investment principles [2]. - Risk control measures include selecting reputable financial institutions and products, conducting pre-investment risk assessments, and maintaining regular audits and oversight [2]. - The internal audit department will supervise fund usage and storage, with independent directors and the audit committee having the authority to monitor and review [2]. Group 3: Impact on the Company - The cash management initiative is expected to improve fund utilization efficiency and generate investment returns, ultimately benefiting the company and its shareholders [3]. - Both the board and the supervisory committee have expressed support for the cash management plan, confirming its legality and alignment with shareholder interests [3]. - The sponsor institution has verified that the necessary review procedures have been followed and will continue to monitor the fund usage [3].